- Home
- FATE vs XGN Comparison
FATE vs XGN Comparison
Compare FATE & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- XGN
- Stock Information
- Founded
- FATE 2007
- XGN 2002
- Country
- FATE United States
- XGN United States
- Employees
- FATE N/A
- XGN N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- XGN Medical Specialities
- Sector
- FATE Health Care
- XGN Health Care
- Exchange
- FATE Nasdaq
- XGN Nasdaq
- Market Cap
- FATE 125.7M
- XGN 138.3M
- IPO Year
- FATE 2013
- XGN 2019
- Fundamental
- Price
- FATE $1.15
- XGN $10.10
- Analyst Decision
- FATE Hold
- XGN Strong Buy
- Analyst Count
- FATE 7
- XGN 4
- Target Price
- FATE $3.58
- XGN $11.75
- AVG Volume (30 Days)
- FATE 1.5M
- XGN 387.3K
- Earning Date
- FATE 08-12-2025
- XGN 07-29-2025
- Dividend Yield
- FATE N/A
- XGN N/A
- EPS Growth
- FATE N/A
- XGN N/A
- EPS
- FATE N/A
- XGN N/A
- Revenue
- FATE $8,470,000.00
- XGN $58,862,000.00
- Revenue This Year
- FATE N/A
- XGN $19.68
- Revenue Next Year
- FATE N/A
- XGN $13.68
- P/E Ratio
- FATE N/A
- XGN N/A
- Revenue Growth
- FATE N/A
- XGN 3.89
- 52 Week Low
- FATE $0.66
- XGN $2.38
- 52 Week High
- FATE $4.20
- XGN $10.34
- Technical
- Relative Strength Index (RSI)
- FATE 53.09
- XGN 77.40
- Support Level
- FATE $1.06
- XGN $9.39
- Resistance Level
- FATE $1.18
- XGN $9.90
- Average True Range (ATR)
- FATE 0.09
- XGN 0.44
- MACD
- FATE 0.02
- XGN 0.03
- Stochastic Oscillator
- FATE 72.73
- XGN 88.52
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.